Zinc oxide nanoparticles: A 90-day repeated-dose dermal toxicity study in rats

Hwa Jung Ryu, Mu Yeb Seo, Sung Kyu Jung, Eun Ho Maeng, Seung Young Lee, Dong Hyouk Jang, Taek Jin Lee, Ki Yeon Jo, Yu Ri Kim, Kyu Bong Cho, Meyoung-Kon Kim, Beom Jun Lee, Sang Wook Son

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Zinc oxide (ZnO) works as a long-lasting, broad-spectrum physical sunblock, and can prevent skin cancer, sunburn, and photoaging. Nanosized ZnO particles are used often in sunscreens due to consumer preference over larger sizes, which appear opaque when dermally applied. Although the US Food and Drug Administration approved the use of nanoparticles (NPs) in sunscreens in 1999, there are ongoing safety concerns. The aim of this study was to evaluate the subchronic toxicity of ZnO NPs after dermal application according to the Organization for Economic Cooperation and Development Test Guidelines 411 using Good Laboratory Practice. Sprague Dawley rats were randomly divided into eight (one control, one vehicle control, three experimental, and three recovery) groups. Different concentrations of ZnO NPs were dermally applied to the rats in the experimental groups for 90 days. Clinical observations as well as weight and food consumption were measured and recorded daily. Hematology and biochemistry parameters were determined. Gross pathologic and histopathologic examinations were performed on selected tissues from all animals. Analyses of tissue were undertaken to determine target organ tissue distribution. There was no increased mortality in the experimental group. Although there was dose-dependent irritation at the site of application, there were no abnormal findings related to ZnO NPs in other organs. Increased concentrations of ZnO in the liver, small intestine, large intestine, and feces were thought to result from oral ingestion of ZnO NPs via licking. Penetration of ZnO NPs through the skin seemed to be limited via the dermal route. This study demonstrates that there was no observed adverse effect of ZnO NPs up to 1,000 mg/kg body weight when they are applied dermally.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalInternational Journal of Nanomedicine
Volume9
DOIs
Publication statusPublished - 2014 Dec 15

Fingerprint

Zinc Oxide
Zinc oxide
Nanoparticles
Toxicity
Rats
Skin
Sun hoods
Sunscreening Agents
Tissue
Sunburn
Biochemistry
Large Intestine
Skin Neoplasms
Hematology
Tissue Distribution
United States Food and Drug Administration
Feces
Liver
Small Intestine
Sprague Dawley Rats

Keywords

  • Dermal exposure
  • Nanoparticles
  • Subchronic toxicity
  • Zinc oxide

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Organic Chemistry
  • Drug Discovery

Cite this

Zinc oxide nanoparticles : A 90-day repeated-dose dermal toxicity study in rats. / Ryu, Hwa Jung; Seo, Mu Yeb; Jung, Sung Kyu; Maeng, Eun Ho; Lee, Seung Young; Jang, Dong Hyouk; Lee, Taek Jin; Jo, Ki Yeon; Kim, Yu Ri; Cho, Kyu Bong; Kim, Meyoung-Kon; Lee, Beom Jun; Son, Sang Wook.

In: International Journal of Nanomedicine, Vol. 9, 15.12.2014, p. 137-144.

Research output: Contribution to journalArticle

Ryu, HJ, Seo, MY, Jung, SK, Maeng, EH, Lee, SY, Jang, DH, Lee, TJ, Jo, KY, Kim, YR, Cho, KB, Kim, M-K, Lee, BJ & Son, SW 2014, 'Zinc oxide nanoparticles: A 90-day repeated-dose dermal toxicity study in rats', International Journal of Nanomedicine, vol. 9, pp. 137-144. https://doi.org/10.2147/IJN.S57930
Ryu, Hwa Jung ; Seo, Mu Yeb ; Jung, Sung Kyu ; Maeng, Eun Ho ; Lee, Seung Young ; Jang, Dong Hyouk ; Lee, Taek Jin ; Jo, Ki Yeon ; Kim, Yu Ri ; Cho, Kyu Bong ; Kim, Meyoung-Kon ; Lee, Beom Jun ; Son, Sang Wook. / Zinc oxide nanoparticles : A 90-day repeated-dose dermal toxicity study in rats. In: International Journal of Nanomedicine. 2014 ; Vol. 9. pp. 137-144.
@article{9e5c2c9b90c64f739cc8f981fc927491,
title = "Zinc oxide nanoparticles: A 90-day repeated-dose dermal toxicity study in rats",
abstract = "Zinc oxide (ZnO) works as a long-lasting, broad-spectrum physical sunblock, and can prevent skin cancer, sunburn, and photoaging. Nanosized ZnO particles are used often in sunscreens due to consumer preference over larger sizes, which appear opaque when dermally applied. Although the US Food and Drug Administration approved the use of nanoparticles (NPs) in sunscreens in 1999, there are ongoing safety concerns. The aim of this study was to evaluate the subchronic toxicity of ZnO NPs after dermal application according to the Organization for Economic Cooperation and Development Test Guidelines 411 using Good Laboratory Practice. Sprague Dawley rats were randomly divided into eight (one control, one vehicle control, three experimental, and three recovery) groups. Different concentrations of ZnO NPs were dermally applied to the rats in the experimental groups for 90 days. Clinical observations as well as weight and food consumption were measured and recorded daily. Hematology and biochemistry parameters were determined. Gross pathologic and histopathologic examinations were performed on selected tissues from all animals. Analyses of tissue were undertaken to determine target organ tissue distribution. There was no increased mortality in the experimental group. Although there was dose-dependent irritation at the site of application, there were no abnormal findings related to ZnO NPs in other organs. Increased concentrations of ZnO in the liver, small intestine, large intestine, and feces were thought to result from oral ingestion of ZnO NPs via licking. Penetration of ZnO NPs through the skin seemed to be limited via the dermal route. This study demonstrates that there was no observed adverse effect of ZnO NPs up to 1,000 mg/kg body weight when they are applied dermally.",
keywords = "Dermal exposure, Nanoparticles, Subchronic toxicity, Zinc oxide",
author = "Ryu, {Hwa Jung} and Seo, {Mu Yeb} and Jung, {Sung Kyu} and Maeng, {Eun Ho} and Lee, {Seung Young} and Jang, {Dong Hyouk} and Lee, {Taek Jin} and Jo, {Ki Yeon} and Kim, {Yu Ri} and Cho, {Kyu Bong} and Meyoung-Kon Kim and Lee, {Beom Jun} and Son, {Sang Wook}",
year = "2014",
month = "12",
day = "15",
doi = "10.2147/IJN.S57930",
language = "English",
volume = "9",
pages = "137--144",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Zinc oxide nanoparticles

T2 - A 90-day repeated-dose dermal toxicity study in rats

AU - Ryu, Hwa Jung

AU - Seo, Mu Yeb

AU - Jung, Sung Kyu

AU - Maeng, Eun Ho

AU - Lee, Seung Young

AU - Jang, Dong Hyouk

AU - Lee, Taek Jin

AU - Jo, Ki Yeon

AU - Kim, Yu Ri

AU - Cho, Kyu Bong

AU - Kim, Meyoung-Kon

AU - Lee, Beom Jun

AU - Son, Sang Wook

PY - 2014/12/15

Y1 - 2014/12/15

N2 - Zinc oxide (ZnO) works as a long-lasting, broad-spectrum physical sunblock, and can prevent skin cancer, sunburn, and photoaging. Nanosized ZnO particles are used often in sunscreens due to consumer preference over larger sizes, which appear opaque when dermally applied. Although the US Food and Drug Administration approved the use of nanoparticles (NPs) in sunscreens in 1999, there are ongoing safety concerns. The aim of this study was to evaluate the subchronic toxicity of ZnO NPs after dermal application according to the Organization for Economic Cooperation and Development Test Guidelines 411 using Good Laboratory Practice. Sprague Dawley rats were randomly divided into eight (one control, one vehicle control, three experimental, and three recovery) groups. Different concentrations of ZnO NPs were dermally applied to the rats in the experimental groups for 90 days. Clinical observations as well as weight and food consumption were measured and recorded daily. Hematology and biochemistry parameters were determined. Gross pathologic and histopathologic examinations were performed on selected tissues from all animals. Analyses of tissue were undertaken to determine target organ tissue distribution. There was no increased mortality in the experimental group. Although there was dose-dependent irritation at the site of application, there were no abnormal findings related to ZnO NPs in other organs. Increased concentrations of ZnO in the liver, small intestine, large intestine, and feces were thought to result from oral ingestion of ZnO NPs via licking. Penetration of ZnO NPs through the skin seemed to be limited via the dermal route. This study demonstrates that there was no observed adverse effect of ZnO NPs up to 1,000 mg/kg body weight when they are applied dermally.

AB - Zinc oxide (ZnO) works as a long-lasting, broad-spectrum physical sunblock, and can prevent skin cancer, sunburn, and photoaging. Nanosized ZnO particles are used often in sunscreens due to consumer preference over larger sizes, which appear opaque when dermally applied. Although the US Food and Drug Administration approved the use of nanoparticles (NPs) in sunscreens in 1999, there are ongoing safety concerns. The aim of this study was to evaluate the subchronic toxicity of ZnO NPs after dermal application according to the Organization for Economic Cooperation and Development Test Guidelines 411 using Good Laboratory Practice. Sprague Dawley rats were randomly divided into eight (one control, one vehicle control, three experimental, and three recovery) groups. Different concentrations of ZnO NPs were dermally applied to the rats in the experimental groups for 90 days. Clinical observations as well as weight and food consumption were measured and recorded daily. Hematology and biochemistry parameters were determined. Gross pathologic and histopathologic examinations were performed on selected tissues from all animals. Analyses of tissue were undertaken to determine target organ tissue distribution. There was no increased mortality in the experimental group. Although there was dose-dependent irritation at the site of application, there were no abnormal findings related to ZnO NPs in other organs. Increased concentrations of ZnO in the liver, small intestine, large intestine, and feces were thought to result from oral ingestion of ZnO NPs via licking. Penetration of ZnO NPs through the skin seemed to be limited via the dermal route. This study demonstrates that there was no observed adverse effect of ZnO NPs up to 1,000 mg/kg body weight when they are applied dermally.

KW - Dermal exposure

KW - Nanoparticles

KW - Subchronic toxicity

KW - Zinc oxide

UR - http://www.scopus.com/inward/record.url?scp=84929409344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929409344&partnerID=8YFLogxK

U2 - 10.2147/IJN.S57930

DO - 10.2147/IJN.S57930

M3 - Article

C2 - 25565832

AN - SCOPUS:84929409344

VL - 9

SP - 137

EP - 144

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -